Over 50 companies advance 55+ new pulmonary arterial hypertension drugs in clinical trials.

More than 50 companies are actively developing over 55 new drugs for pulmonary arterial hypertension (PAH), a serious lung-related heart condition. These drugs are in various clinical trial stages, with several in late-stage development, aiming to improve treatment options and patient outcomes. Major pharmaceutical firms like Pfizer, GSK, and United Therapeutics are leading innovations with novel therapies targeting different biological pathways. This surge in clinical research highlights a growing focus on addressing unmet medical needs and advancing PAH treatment globally.